212 related articles for article (PubMed ID: 7049369)
1. Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites.
Rustum YM; Danhauser L; Luccioni C; Au JL
Cancer Treat Rep; 1981; 65 Suppl 3():73-82. PubMed ID: 7049369
[TBL] [Abstract][Full Text] [Related]
2. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
Riva CM; Rustum YM
Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
[TBL] [Abstract][Full Text] [Related]
3. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of action of 5-FU: biochemical basis.
Rustum YM; Danhauser L; Wang G
Bull Cancer; 1979; 66(1):43-7. PubMed ID: 154352
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
Chou TC; Hutchinson DJ; Schmid FA; Philips FS
Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
[TBL] [Abstract][Full Text] [Related]
6. The target cell determinants of the antitumor actions of 5-FU: does FU incorporation into RNA play a role?
Mandel HG
Cancer Treat Rep; 1981; 65 Suppl 3():63-71. PubMed ID: 6179616
[TBL] [Abstract][Full Text] [Related]
7. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion.
Myers CE; Young RC; Chabner BA
J Clin Invest; 1975 Nov; 56(5):1231-8. PubMed ID: 1184747
[TBL] [Abstract][Full Text] [Related]
8. [Biochemical modulation in cancer chemotherapy].
Kawasaki H; Nobori T; Kamiya H; Sakurai M
Gan To Kagaku Ryoho; 1985 Apr; 12(4):815-29. PubMed ID: 3985645
[TBL] [Abstract][Full Text] [Related]
9. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacology of anticancer agents (Part 4). Antimetabolites (1)].
Nakamura T; Uchida M; Ueda T
Gan To Kagaku Ryoho; 1992 Feb; 19(2):265-76. PubMed ID: 1736842
[TBL] [Abstract][Full Text] [Related]
11. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.
Cao D; Russell RL; Zhang D; Leffert JJ; Pizzorno G
Cancer Res; 2002 Apr; 62(8):2313-7. PubMed ID: 11956089
[TBL] [Abstract][Full Text] [Related]
12. On the rational development of a new drug: the example of the fluorinated pyrimidines.
Heidelberger C
Cancer Treat Rep; 1981; 65 Suppl 3():3-9. PubMed ID: 7346154
[TBL] [Abstract][Full Text] [Related]
13. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
14. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
Danhauser LL; Rustum YM
Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
17. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
18. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
19. [The metabolism of high-molecular-weight substances in cells and the effect of anticancer drugs].
Kanamaru R; Kakuta H; Sato T; Ishioka C; Konishi Y; Wakui A; Dei T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):837-44. PubMed ID: 3566294
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells.
Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H
Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
